Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

13.36 -1.62 (-10.81%)
Streaming Delayed Price Updated: 11:19 AM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
uniQure Narrows Loss in Fiscal Q2
Via The Motley Fool
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares
uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130. 
Via Chartmill
Earnings Scheduled For July 29, 2025
 
Via Benzinga
uniQure Earnings Preview
 
Via Benzinga
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode
The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 
Via Stocktwits
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Earnings Outlook For uniQure
 
Via Benzinga
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Which stocks are moving on Thursday?
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic
The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130. 
Via Stocktwits
Topics Bankruptcy
There are notable gap-ups and gap-downs in today's session.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
What's going on in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses. 
Via Benzinga
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Via The Motley Fool
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
 
Via Benzinga
Topics Stocks
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
 
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
 
Via Benzinga
Topics Stocks
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
Why Is uniQure Stock Skyrocketing On Tuesday?
uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130. 
Via Benzinga
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Why Are UniQure Shares Surging Today?
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's... 
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS